A Phase II Study of Weekly Docetaxel Plus Capecitabine for Patients with Advanced Nonsmall Cell Lung Carcinoma

Cancer

Volumn 98, Issue 9, 2003, Pages 1918-1924

  Han, Ji Youn ^a   Lee, Dae Ho ^a   Kim, Hae Young ^a   Hong, Eun Kyung ^a   Yoon, Sung Min ^a   Chun, Jong Ho ^a   Lee, Hong Gi ^a   Lee, Sung Young ^a   Shin, Eun Hee ^a   Lee, Jin Soo ^a  

^a National Cancer Center   (South Korea)

Author keywords

Capecitabine; Docetaxel; Noncisplatin based chemotherapy; Nonsmall cell lung carcinoma

Indexed keywords

CAPECITABINE; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; INFECTION; LACRIMAL GLAND DISEASE; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; ONYCHOLYSIS; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTHENIA; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; STOMATITIS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0142150096     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11738     Document Type: Article

References (33)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin. 2002;52:23-47.
2. Government of the Republic of Korea. Annual report on the cause of death statistics, 2001. Daejeon: Korea National Statistical Office, 2002.
3. Crino L, Cappuzzo F. Present and future treatment of advanced non-small cell lung cancer. Semin Oncol. 2002;29(Suppl 9):9-16.
4. Cellerino R, Tummarello D, Piga A. Chemotherapy or not in advanced non-small cell lung cancer? Cancer. 1990;6:99-109.
5. Pujol JL, Quantin X, Choma D, Jacot W, Khial F. Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer. Lung Cancer. 2002;38: S57-S60.
6. Cerny T, Kaplan S, Pavlidis N, et al. Docetaxel (Taxotere) is active in non-small cell lung cancer: a Phase II trial of EORTC Early Clinical Trials Group (ECTG). Br J Cancer. 1994;70:384-387.
7. Francis PA, Rigas JR, Kris MG, et al. Phase II trial of docetaxel in patients with Stage III and IV non-small cell lung cancer. J Clin Oncol. 1997;12:1232-1237.
8. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer. 1995;75:968-972.
9. Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol. 1994;12:1238-1244.
10. Kunitah H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol. 1996;14:1649-1655.
11. Georgoulias V, Androulakis N, Dimopoulos AM, et al. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter Phase II study. Ann Oncol. 1998;9:331-334.
12. Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol. 1998;16:1948-1953.
13. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998;34:1274-1281.
14. Schüller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 2000;34:293-296.
15. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res. 1998;4:1013-1019.
16. Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5′ -deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin Cancer Res. 2001;7:1079-1086.
17. Kurosumi M, Tabei T, Suemasu K, et al. Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients. Oncol Rep. 2000;7:945-948.
18. Giatromanolaki A, Koukourakis MI, Comley M, et al. Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. J Pathol. 1997;181:196-199.
19. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J Clin Oncol. 2002;20:2812-2823.
20. Hainsworth JD, Burris HA III, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
21. Hainsworth JD, Burris HA III, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network Phase II trial. J Clin Oncol. 2001;19:3500-3505.
22. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: World Health Organization, 1979.
23. Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1998;10:1-10.
24. Kaplan ES, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc. 1958;53:457-481.
25. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288.
26. Fox SB, Engels K, Comley M. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol. 1997;8:271-275.
27. Villalona-Calero MA, Weiss GR, Burris HA, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol. 1999;17:1915-1925.
28. Pronk LC, Vasey P, Sparreboom A, et al. A Phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer. 2000;83:22-29.
29. Meza LA, Amin B, Horsey M, et al. A Phase II study of capecitabine in combination with paclitaxel as first or second line therapy in patients with metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol. 2001;20:70b.
30. Villalona-Calero MA, Blum JL, Jones SE, et al. A Phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol. 2001;12:605-614.
31. Nadella P, Shapiro C, Otterson GA, et al. Pharmacobiologically based scheduling of capecitabine and docetaxel results in antitumor activity in resistant human malignancies. J Clin Oncol. 2002;20:2616-2623.
32. Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002;13:218-221.
33. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097-4106.